Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OT48WOL1)

DOT Name Bestrophin-2 (BEST2)
Synonyms Vitelliform macular dystrophy 2-like protein 1
Gene Name BEST2
Related Disease
Acute myelogenous leukaemia ( )
Barrett esophagus ( )
Ulcerative colitis ( )
UniProt ID
BEST2_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
8D1E; 8D1F; 8D1G; 8D1H
Pfam ID
PF01062
Sequence
MTVTYTARVANARFGGFSQLLLLWRGSIYKLLWRELLCFLGFYMALSAAYRFVLTEGQKR
YFEKLVIYCDQYASLIPVSFVLGFYVTLVVNRWWSQYLCMPLPDALMCVVAGTVHGRDDR
GRLYRRTLMRYAGLSAVLILRSVSTAVFKRFPTIDHVVEAGFMTREERKKFENLNSSYNK
YWVPCVWFSNLAAQARREGRIRDNSALKLLLEELNVFRGKCGMLFHYDWISVPLVYTQVV
TIALYSYFLACLIGRQFLDPAQGYKDHDLDLCVPIFTLLQFFFYAGWLKVAEQLINPFGE
DDDDFETNFLIDRNFQVSMLAVDEMYDDLAVLEKDLYWDAAEARAPYTAATVFQLRQPSF
QGSTFDITLAKEDMQFQRLDGLDGPMGEAPGDFLQRLLPAGAGMVAGGPLGRRLSFLLRK
NSCVSEASTGASCSCAVVPEGAAPECSCGDPLLDPGLPEPEAPPPAGPEPLTLIPGPVEP
FSIVTMPGPRGPAPPWLPSPIGEEEENLA
Function Forms calcium-sensitive chloride channels. Permeable to bicarbonate.
Tissue Specificity Mainly confined to the retinal pigment epithelium and colon.
KEGG Pathway
Salivary secretion (hsa04970 )
Reactome Pathway
Stimuli-sensing channels (R-HSA-2672351 )

Molecular Interaction Atlas (MIA) of This DOT

3 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Acute myelogenous leukaemia DISCSPTN Strong Genetic Variation [1]
Barrett esophagus DIS416Y7 Strong Genetic Variation [2]
Ulcerative colitis DIS8K27O Strong Altered Expression [3]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
2 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Estradiol DMUNTE3 Approved Estradiol increases the expression of Bestrophin-2 (BEST2). [4]
SNDX-275 DMH7W9X Phase 3 SNDX-275 increases the expression of Bestrophin-2 (BEST2). [5]
------------------------------------------------------------------------------------
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene increases the methylation of Bestrophin-2 (BEST2). [6]
------------------------------------------------------------------------------------

References

1 KIR Donor Selection: Feasibility in Identifying better Donors.Biol Blood Marrow Transplant. 2019 Jan;25(1):e28-e32. doi: 10.1016/j.bbmt.2018.08.022. Epub 2018 Aug 24.
2 Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.Lancet Gastroenterol Hepatol. 2017 Jan;2(1):23-31. doi: 10.1016/S2468-1253(16)30118-2. Epub 2016 Nov 11.
3 Lineage-specific expression of bestrophin-2 and bestrophin-4 in human intestinal epithelial cells.PLoS One. 2013 Nov 5;8(11):e79693. doi: 10.1371/journal.pone.0079693. eCollection 2013.
4 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
5 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
6 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.